Epitope Modification
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Dec 26, 2024
app pub date -
Aug 23, 2022
filing date -
Aug 23, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention relates to epitope modification based on a chemical cross-linking reactive group and the use thereof in changing the immunogenicity of an antigen and enhancing animal immune response to a target epitope of an antigen. The present invention relates to the administration of a mutant antigen incorporated by a group with chemical cross-slinking activity on the target epitope of a wild-type antigen or derivative thereof to an animal, wherein the antibody reaction in the animal is directed and enriched to the target epitope of the mutant antigen. Provided are a method for selecting antibodies against a target epitope of an antigen and the antibodies obtained thereby; further provided is the use of the method in the preparation of a vaccine for preventing and treating diseases.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully